<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210519051343N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-24</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of durability of fat injection with Hyaluronic acid gel (Profhilo)</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of the durability of fat injection alone with respect to fat injection along with the  injection of Hyaluronic Acid gel(Profhilo) in the cheeks of patients referred to Razi Hospital in the years 1399-1400</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>10</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56838</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Excel software will be used for randomization. In one column, 5 letters A and 5 letters B are recorded, and in the adjacent column, 10 random numbers are created with the Rand () command. The sequence of both columns is then sorted from large to small based on a column of random numbers. The sequence obtained for the letters A and B will be the criteria for entering the two groups of intervention and control, Blinding description: After doing the procedures  and taking photographs, the other two dermatologists will  separately look at the photographs  taken at each visit and will give a score based on the photographs.</study_design>
      <phase>2-3</phase>
      <hc_freetext>autologous fat transplant with and without Profhilo hyaluronic acid gel.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The group that undergoes hyaluronic acid gel injection after fat injection - selected fat donor sites of the outer thigh. Aspiration is done with a cannula to collect the fat pieces. Then the obtained liquid is centrifuged and then the fat is separated as a yellow and smooth layer and this layer of fat is injected with a 2 ml syringe and canola number 14 can be used. About 30 ml of total fat is injected into the cheeks on both sides. After injection, antibiotics and anti-inflammatory drugs are prescribed. Hyaluronic Acid gel (profhilo) with a dose of 2 ml per session (1 ml on each side of the cheek)is then injected during 2 sessions at intervals 2 and 4 weeks after fat injection. The profhilo injection is done according to the 5 point technique. Intervention 2: Control group: In this group, patients are injected only with fat, which is extracted from the outer part of the thigh and centrifuged, and about 30 ml is injected in each cheek on each side of the patient's face. Patients in this group are not injected with profhilo gel.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data will be accessible for academic researchers after covering the identities

When:
after being published by the journal, all data will be accessible forever

To whom:
for all academic researchers in the field of medicine and pharmacology

Conditions:
Just for using in research fields and respecting the original researchers in any referencing

Where to obtain:
emailing the main researcher via this email: marwaakhdar@live.com

How to obtain:
just an email containing information about the academic position of the researchers and their responsibilities

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Houshang Ehsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi hospital- razi alley-vahdat esmali square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5563 0223</telephone>
        <email>ehsanih@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amir Houshang Ehsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi hospital-razi alley- vahdat eslami square</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5563 0223</telephone>
        <email>ehsanih@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age between 18 and 70 years old
score of Wrinkle Severity Rating Scale  between 2-4
patients who don't want to do surgical procedures
signing an inform consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Candidate for cosmetic facial surgery
pregnancy and lactation
neuromuscular disease
uncontrolled systemic disease
infection, scar, or abnormality at the site of injection
a history of filler or fat injection in the past 12 months
patients under treatment with immunosuppressive drugs, aspirin, narcotics, antidepressants, and corticosteroids
history of adverse reactions to hyaluronic acid gel and other gels
history of adverse reaction to tumescent solution
adverse reactions to injection instruments( needle and cannula)
facial asymmetry</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z41.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for cosmetic surgery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The group that undergoes hyaluronic acid gel injection after fat injection - selected fat donor sites of the outer thigh. Aspiration is done with a cannula to collect the fat pieces. Then the obtained liquid is centrifuged and then the fat is separated as a yellow and smooth layer and this layer of fat is injected with a 2 ml syringe and canola number 14 can be used. About 30 ml of total fat is injected into the cheeks on both sides. After injection, antibiotics and anti-inflammatory drugs are prescribed. Hyaluronic Acid gel (profhilo) with a dose of 2 ml per session (1 ml on each side of the cheek)is then injected during 2 sessions at intervals 2 and 4 weeks after fat injection. The profhilo injection is done according to the 5 point technique.</i_keyword>
      <i_keyword>Control group: In this group, patients are injected only with fat, which is extracted from the outer part of the thigh and centrifuged, and about 30 ml is injected in each cheek on each side of the patient's face. Patients in this group are not injected with profhilo gel.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Specialist's score based on GAIS-doctor score. Timepoint: baseline-1 month after -6 months after. Method of measurement: Measurement based on the score given by the non-executive physician based on GAIS-doctor score which includes 7 scores:1- very  much improved.2-: much improved.3-: improved.4-: no change.5-worse.6- much worse.7- very much worse.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Wrinkle severity. Timepoint: baseline-1 month after- 6 months after. Method of measurement: measurement is done according to the Wrinkle Severity Rating Scale (WSRS) scoring system which includes 5 scores:0- Absent.1- Slight wrinkles.2-Quite evident wrinkles.3-Evident wrinkles.4-Marked wrinkles.5-Very marked wrinkles.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>IBSA pharmeceutics</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
      <source_name>Paeezan Tejarat Mehr</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-12</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>vahdat islami square-vahdat islami street-razi hospital Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
